Clinical Trials
10 trialsNCT00719173 2024-11-04
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT05841849 2023-05-03
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4 Not yet recruiting
NCT01298193 2023-03-07
Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.
Spanish Breast Cancer Research Group
Phase 4 Completed
NCT02336750 2022-04-20
Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis
Fudan University
Phase 3 Completed
NCT00248547 2017-05-09
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
OHSU Knight Cancer Institute
Phase NA Completed
NCT00092183 2017-05-05
An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT00092196 2017-05-05
Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00293384 2016-03-15
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
Phase NA Completed
NCT00475085 2015-11-10
Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial
University of Rochester
Phase 3 Completed
NCT00869973 2013-01-23
Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients
S. Maria Hospital, Terni
Phase 3 Terminated